Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5601-5610 Newer>

Reason May 2009 Ronald Bailey	Hips Abroad Medical outsourcing
The Motley Fool April 30, 2009 Brian Orelli	A Great Generic Recovery After getting punished for taking on an acquisition, Mylan is doing pretty well.
The Motley Fool April 30, 2009 Brian Orelli	How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome.
CIO April 27, 2009 James Niccolai	Home Healthcare Devices Help Patients Stay out of the Hospital Remote devices allow patients to monitor their health at home and reduce hospital visits.
The Motley Fool April 29, 2009 Brian Orelli	Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising.
The Motley Fool April 29, 2009 Brian Orelli	The Other 33.1% of Pfizer Reports The take-home message for current and future Pfizer shareholders from Wyeth's quarterly report is that they're not getting a growth monster, but Wyeth's revenue is fairly stable.
The Motley Fool April 29, 2009 Brian Orelli	2 Lessons From Dendreon Traders beware.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool April 27, 2009 Jim Mueller	Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock.
<Older 5601-5610 Newer> Return to current articles.